Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy - PubMed (original) (raw)

doi: 10.1016/j.ultrasmedbio.2015.08.008. Epub 2015 Sep 19.

Stéphane Audière 2, Astrid Kemgang 3, Farid Gaouar 3, Christophe Corpechot 3, Olivier Chazouillères 3, Céline Fournier 4, Olivier Golsztejn 5, Stéphane Prince 5, Yves Menu 5, Laurent Sandrin 2, Véronique Miette 2

Affiliations

Liver Steatosis Assessed by Controlled Attenuation Parameter (CAP) Measured with the XL Probe of the FibroScan: A Pilot Study Assessing Diagnostic Accuracy

Magali Sasso et al. Ultrasound Med Biol. 2016 Jan.

Abstract

To assess liver steatosis, the controlled attenuation parameter (CAP; giving an estimate of ultrasound attenuation ∼3.5 MHz) is available with the M probe of the FibroScan. We report on the adaptation of the CAP for the FibroScan XL probe (center frequency 2.5 MHz) without modifying the range of values (100-400 dB/m). CAP validation was successfully performed on Field II simulations and on tissue-mimicking phantoms. In vivo performance was assessed in a cohort of 59 patients spanning the range of steatosis. In vivo reproducibility was good and similar with both probes. The area under receiver operative characteristic curve was equal to 0.83/0.84 and 0.92/0.91 for the M/XL probes to detect >2% and >16% liver fat, respectively, as assessed by magnetic resonance imaging. Patients can now be assessed simultaneously for steatosis and fibrosis using the FibroScan, regardless of their morphology.

Keywords: Controlled attenuation parameter (CAP); Elastography; FibroScan; Liver; Non-alcoholic fatty liver disease (NAFLD); Steato-hepatitis; Steatosis; Ultrasound attenuation; Vibration-controlled transient elastography (VCTE).

Copyright © 2016 World Federation for Ultrasound in Medicine & Biology. Published by Elsevier Inc. All rights reserved.

PubMed Disclaimer

MeSH terms

LinkOut - more resources